Comerica Bank
SPRY icon

Comerica Bank’s ARS Pharmaceuticals SPRY Stock Holding History

Comerica Bank’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.53K Buy
217
+99
+84% +$963 ﹤0.01% 3502
2025
Q3 		$1.19K Buy
+118
New +$1.69K ﹤0.01% 3578
2024
Q2 		– Sell
-140
Closed -$1.43K – 3810
2024
Q1 		$1.43K Buy
+140
New +$1.04K ﹤0.01% 3583

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Comerica Bank's SPRY Position: Q4 2025 in Review

Comerica Bank increased its ARS Pharmaceuticals (SPRY) stake by 84% in Q4 2025, buying an estimated $963 and bringing the position to 217 shares worth $2.53K. The position accounts for ﹤0.01% of the portfolio, ranked #3502.

Comerica Bank first reported a position in SPRY in Q1 2024 and has held it in 3 quarters since. 189 funds tracked by Wall St. Rank hold SPRY as of Q4 2025.

  • Comerica Bank held 217 shares of ARS Pharmaceuticals worth $2.53K as of Q4 2025.
  • Comerica Bank bought 99 ARS Pharmaceuticals shares in Q4 2025, an estimated $963.
  • ARS Pharmaceuticals made up ﹤0.01% of Comerica Bank's portfolio in Q4 2025, its #3502 holding.
  • Comerica Bank first reported a position in ARS Pharmaceuticals in Q1 2024 and has held it in 3 quarters since.
  • 189 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q4 2025.

Based on Comerica Bank's 13F filing for Q4 2025, filed 29 Jan 2026.